Nausea and vomiting
2 papers
- Human trial1
- Humans1
Trial sponsors
Company1 trialPhase 31,428 people
Company1 trialPhase 31,428 people
Company1 trialPhase 3150 people
Company1 trialPhase 2492 people
The Second Affiliated Hospital of Chongqing Medical University
1 trialPhase 4200 people
Alliance for Clinical Trials in Oncology
2 trialsPhase 3831 people
Cambridge University Hospitals NHS Foundation Trust
1 trialPhase 3320 people
1 trialPhase 3267 people
Latest
6 in 12 monthsInternational Medical Case Reports Journal
Severe Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report
Case reportSemaglutide
American Journal of Clinical Oncology
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Adverse Events in Patients Receiving Platinum Analog-Based Chemotherapy
Cohort study of 200 peopleGLP-1 receptor agonists
Case Reports in Neurology
Acute Nutritional Axonal Neuropathy in the Setting of Semaglutide-Associated Gastrointestinal Intolerance: A Case Report
Case reportSemaglutide
ADA Scientific Sessions 2026 Abstract
MDR-001, an AI-Enabled β-arrestin2-Biased Oral GLP-1RA: Efficacy and Safety in Chinese Adults with Overweight or Obesity
Randomised trial in 317 peopleOverweight
International Journal of Emergency Medicine
Starvation ketoacidosis associated with tirzepatide use for weight loss in a non-diabetic East Asian woman: a case report
Case reportTirzepatide
AHA Scientific Sessions 2025 Abstract
Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist Reduces Liver Fat Content along with Blood Pressure in Post-menopausal Females with Obesity: A Phase 1a/2b Study
Randomised trial in 48 peopleObesity
ENDO 2025 Abstract
SAT-277 Efficacy And Safety Of Lipoprotein Apheresis In ASCVD Patients With Elevated Lipoprotein(a): A Multicenter Retrospective Study
Cohort study of 60 peopleInterventions
ENDO 2025 Abstract
SAT-713 Phase 2 Clinical Trials Of Na-931 To Study Subjects Who Are Obese With At Least One Weight-related Comorbid Condition
Randomised trial in 125 peopleComorbidity
ADA Scientific Sessions 2025 Abstract
Efficacy and Safety of a Novel Dual GLP-1/GLP Receptor Agonist in Chinese Overweight or Obese Adults without Diabetes
Randomised trial in 61 peopleOverweight
ADA Scientific Sessions 2025 Abstract
Tirzepatide in Type 1 Diabetes—Safety, Tolerability, and Clinical Outcomes—Real-World Experience from a Large UK Center
Cohort study of 58 peopleTirzepatide